Brian J. McMahon

TL;DR: There is no established benefit of treatment of children in the immune tolerant phase, and there is a very high risk of development of drug resistance, so a conservative approach is warranted.

TL;DR: In this paper, the authors measured the immune response to a 5 microg recombinant vaccine booster dose and found that the proportion of participants with serologic evidence of protective immunity (antibody to hepatitis B surface antigen > or = 10 mIU/mL) at baseline (prebooster), the proportion who developed an anamnestic response (increase to > or ≥ 10 miu/mL or at or more than fourfold increase in antibody to hepatitis b surface antigen to > 10 m IU/mL), and the geometric mean concentration by 1, 2, and 4

TL;DR: Patients who are HBsAg-negative/anti-HBc–positive should be monitored by measuring aminotransferase and HBV DNA levels, and antiviral therapy should be initiated at the first sign of HBV-related hepatitis, as well as all-cause, mortality.

TL;DR: In children with chronic HBV infection, antivirals compared to no antiviral therapy improve HBV DNA suppression and frequency of alanine aminotransferase normalization and HBeAg seroconversion.